Understand the source comparison
Adamax Safety Profile: Research Comparison
The table below compares Adamax to structurally related melanocortin peptides across key safety and research parameters. This is not a therapeutic comparison. It is a research tool comparison for labs evaluating peptide options. Adamax MC4R, MC1R (selective) N
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares Adamax to structurally related melanocortin peptides across key safety and research parameters. This is not a therapeutic comparison. It is a research tool comparison for labs evaluating peptide options.
- Adamax
- MC4R, MC1R (selective)
- Nausea, hyperpigmentation (rodent models); no human data
- 4–6 hours (rodent PK)
- Minimal in preclinical models; human threshold unknown
- Best for short-duration metabolic research; lacks long-term human safety data
- Setmelanotide
- MC4R (highly selective)
- Injection site reactions (20%), nausea (15%), hyperpigmentation (10%); FDA-approved
- 20–24 hours
- No significant cardiovascular effects at therapeutic doses
- Gold standard for MC4R research; human safety data through 52 weeks
- Melanotan II
- MC1R, MC4R, MC3R (non-selective)
- Nausea (40–60%), flushing (20–30%), spontaneous erections (15–25%), hyperpigmentation (universal)
- 30–60 minutes
- Transient tachycardia and hypertension reported
- High adverse event rate; useful for understanding multi-receptor effects
- Alpha-MSH
- MC1R, MC3R, MC4R, MC5R (pan-agonist)
- Transient BP increase (+8–12 mmHg), HR increase (+10–15 bpm), nausea (30%)
- 20–30 minutes
- Cardiovascular effects well-documented but transient
- Short half-life limits research utility; best for acute receptor pharmacology studies
- Adamax occupies a middle ground: more selective than Melanotan II, shorter-acting than setmelanotide, and entirely lacking the human clinical data that makes setmelanotide the safer choice for translational research. For labs studying acute MC4R signaling without the confounding variables of multi-day receptor occupancy, Adamax is mechanistically appropriate. For labs planning studies that could eventually inform human therapeutic development, setmelanotide's established safety profile makes it the better comparator.